key: cord-0950805-2ciqz5bk
authors: LOFGREN, S. M. M.; Nicol, M. R.; Bangdiwala, A. S.; Pastick, K. A.; Okafor, E. C.; Skipper, C. P.; Pullen, M. F.; Engen, N. W.; Abassi, M.; Williams, D. A.; Nascene, A. A.; Axelrod, M. L.; Lother, S. A.; MacKenzie, L. J.; Drobot, G.; Marten, N.; Cheng, M. P.; Zarychanshi, R.; Schwartz, I. S.; Silverman, M.; Chagla, Z.; Kelley, L. E.; McDonald, E. G.; Lee, T. C.; Hullsiek, K. H.; Boulware, D. R.; Rajasingham, R.
title: Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19
date: 2020-07-23
journal: medRxiv : the preprint server for health sciences
DOI: 10.1101/2020.07.16.20155531
sha: 1badaee594d32aa0029fd44c7224921bb5e39eee
doc_id: 950805
cord_uid: 2ciqz5bk

Introduction: Use of hydroxychloroquine in hospitalized patients with COVID-19, especially in combination with azithromycin, has raised safety concerns. Here, we report safety data from three outpatient randomized clinical trials. Methods: We conducted three randomized, double-blind, placebo-controlled trials investigating hydroxychloroquine as pre-exposure prophylaxis, post-exposure prophylaxis and early treatment for COVID-19. We excluded individuals with contraindications to hydroxychloroquine. We collected side effects and serious adverse events. We report descriptive analyses of our findings. Results: We enrolled 2,795 participants. The median age of research participants was 40 (IQR 34-49) years, and 59% (1633/2767) reported no chronic medical conditions. Overall 2,324 (84%) participants reported side effect data, and 638 (27%) reported at least one medication side effect. Side effects were reported in 29% with daily, 36% with twice weekly, 31% with once weekly hydroxychloroquine compared to 19% with placebo. The most common side effects were upset stomach or nausea (25% with daily, 18% with twice weekly, 16% with weekly, vs. 10% for placebo), followed by diarrhea, vomiting, or abdominal pain (23% for daily, 16% twice weekly, 12% weekly, vs. 6% for placebo). Two individuals were hospitalized for atrial arrhythmias, one on placebo and one on twice weekly hydroxychloroquine. No sudden deaths occurred. Conclusion: Data from three outpatient COVID-19 trials demonstrated that gastrointestinal side effects were common but mild with the use of hydroxychloroquine, while serious side effects were rare. No deaths occurred related to hydroxychloroquine. Randomized clinical trials can safely investigate whether hydroxychloroquine is efficacious for COVID-19.

dosing for PREP was dosed at 400 mg orally once, followed by 400mg 6 to 8 hours later, 1 3 9 thereafter 400mg weekly or twice weekly for the duration of follow-up, up to 12 weeks. The old, had an allergy to hydroxychloroquine, retinal eye disease, known glucose-6 phosphate 1 4 7 dehydrogenase (G6PD) deficiency, known chronic kidney disease, stage 4 or 5 or receiving 1 4 8 dialysis, known porphyria, weight <40 kg, known QT prolongation, or receiving chemotherapy.

Current use of hydroxychloroquine, azithromycin, or cardiac arrhythmia medicines (flecainide, 1 5 0 amiodarone, digoxin, procainamide, propafenone, or sotalol) were also exclusion criteria. On

April 20, 2020, the FDA required additional exclusions of structural or ischemic heart disease 1 5 2 and personal or family history of cardiac QT prolongation, and medications that prolong the QTc 1 5 3 interval.

Health Canada mandated additional exclusions for Canadian participants. Women who 1 5 5 were pregnant or breastfeeding were excluded, as were patients with: severe diarrhea or 1 5 6 vomiting; known cirrhosis with a history of encephalopathy or ascites; known prolonged cardiac 1 5 7

QTc interval, history of ventricular arrhythmia or history of sudden cardiac death; patients taking 1 5 8 additional medicines that had a high risk of prolonging the electrocardiogram QTc interval in 1 5 9 conjunction with hydroxychloroquine. The Institutional Review Board (IRB) in Ontario also 1 6 0 mandated that a physician perform a complete review of medications for participants above age 1 6 1 65, to exclude those with important drug-drug interactions.

Participants in the PEP and PET trials completed follow-up email surveys on Days 1, 3, 1 6 3 5, 10, and 14, whereas participants in the PREP trial completed weekly follow-up surveys.

Surveys obtained self-report of study drug adherence, side effects, new COVID-19 symptoms, 1 6 5 new COVID-19 testing, and hospitalization. For participants who stopped their study drug due to 1 6 6 side effects or other reasons, we encouraged them to continue observational follow-up and 1 6 7 completion of self-report surveys. responders. Approximately 66% of the participants were taking no chronic medications, and 1 8 8

Of 1139 who started study drug and reported side effect data, 29% reported one or Similar to the other trials, the most common side effects reported were upset stomach or 2 2 2 nausea (18% on hydroxychloroquine twice weekly, 16% on hydroxychloroquine weekly, and 2 2 3 12% on placebo), followed by vomiting, diarrhea, or other GI symptoms (16% on 2 2 4 hydroxychloroquine twice weekly, 12% on hydroxychloroquine weekly, and 6% on placebo).

Two participants experienced atrial arrhythmias. One participant on placebo was hospitalized 2 2 6 twice with atrial fibrillation. Another participant on hydroxychloroquine twice weekly was 2 2 7 hospitalized after a syncopal event and was found to have a supraventricular tachycardia. No 2 2 8 ventricular arrhythmias were reported.

In total, across the three cohorts, 25 individuals have been hospitalized through June 25, 2 3 0 2020 (1% incidence). The PEP trial had two hospitalizations, one in each arm and no deaths.

The PET trial had 14 hospitalizations and two deaths. With hydroxychloroquine, 4 2 3 2 hospitalizations and 1 non-hospitalized death occurred. With placebo, 10 hospitalizations 2 3 3 occurred with one hospitalized death. Two hospitalizations were for non-COVID-19, non-study 2 3 4 medication related reasons, while the remaining 12 hospitalizations were due to COVID-19.

Nine individuals were hospitalized from the PREP study, one for COVID-19, two for arrhythmias 2 3 6 (one on hydroxychloroquine twice a day and one on placebo), and the other seven 

Hydroxychloroquine prolongs the QT interval and therefore is associated with an increased risk Despite our rational design of these clinical trials, several limitations still exist. A 2 9 8 significant limitation of our studies is related to their pragmatic nature, which relied on accurate 2 9 9 self-reporting. We did not prospectively record or evaluate for laboratory abnormalities or QTc 3 0 0 changes. While we have outcome data on 93% of participants who have completed the studies, 3 0 1 it is possible, given the passive nature of self-reported follow-up, that those lost-to-follow-up 3 0 2 may have had an adverse event that was not reported to our study team or their designated 3 0 3 emergency contacts. Additionally, our cohorts are relatively young, with a median age of 40.

They had few comorbidities and were on few medications. They were also predominantly 

N (%) White or Caucasian

Black or African American 72 (2.6%)

Other or Not Stated 68 (2.5%)

Healthcare worker/First Responder, N (%) 2059 (74.4%)

No medications listed, N (%) 1825 (66.0%)

Authors are actively involved in clinical trials to prevent or treat COVID-3 2 3 19. No author has a financial interest in remote EKG monitoring products or services. Cardiomyocytes are Susceptible to SARS-CoV-2 Infection. bioRxiv 2020.